Trials / Completed
CompletedNCT02309918
HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- HepNet Study House, German Liverfoundation · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single arm, multicenter, pilot-study to compare the efficacy and safety of LDV/SOF fixed dose combination (FDC) in subjects with acute genotype 1 HCV infection. A total of 20 subjects will be assigned to receive LDV/SOF FDC tablet (LDV 90 mg/SOF 400 mg/) once daily for 6 weeks.Patients will be followed up for 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LDV/SOF FDC | Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-12-05
- Last updated
- 2017-08-28
Locations
20 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02309918. Inclusion in this directory is not an endorsement.